信达生物：2025 年上半年业绩，预计因 1H 最热的 ph3 试验推动 IB363 开发加速，下半年利润更高

28 August 2025 | 12:32AM HKT Innovent Biologics (1801.HK): Earnings Review: Expect higher FY profit with 1H beat; first ph3 MRCT to accelerate IBI363 development Higher profit with deepening operating efficiency: 1H25 revenues of Rmb5.95bn (+51% y/y, vs. GSe Rmb5.94bn) were in-line, with 1) Rmb5.2bn of product sales (+37% y/y, as disclosed in early August, see our note) driven by the expanding commercial franchise (16 products in total), particularly the growing General Medicines portfolio, with the sales r ...